Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 122 entries
Sorted by: Best Match Show Resources per page
Incidence of health insurance claims for thyroid neoplasm and pancreatic malignancy in association with exenatide: signal refinement using active safety surveillance.

Therapeutic advances in drug safety

Dore DD, Seeger JD, Chan KA.
PMID: 25083233
Ther Adv Drug Saf. 2012 Aug;3(4):157-64. doi: 10.1177/2042098612446473.

OBJECTIVES: As part of a regulatory postmarketing commitment, we assessed the risk of claims for thyroid and pancreatic cancer among users of exenatide using an active drug safety surveillance system.METHODS: This active surveillance assessment used cohort methodology and commercial...

Cite
Dore DD, Seeger JD, Chan KA. Incidence of health insurance claims for thyroid neoplasm and pancreatic malignancy in association with exenatide: signal refinement using active safety surveillance. Ther Adv Drug Saf. 2012;3(4):157-64doi: 10.1177/2042098612446473.
Dore, D. D., Seeger, J. D., & Chan, K. A. (2012). Incidence of health insurance claims for thyroid neoplasm and pancreatic malignancy in association with exenatide: signal refinement using active safety surveillance. Therapeutic advances in drug safety, 3(4), 157-64. https://doi.org/10.1177/2042098612446473
Dore, David D, et al. "Incidence of health insurance claims for thyroid neoplasm and pancreatic malignancy in association with exenatide: signal refinement using active safety surveillance." Therapeutic advances in drug safety vol. 3,4 (2012): 157-64. doi: https://doi.org/10.1177/2042098612446473
Dore DD, Seeger JD, Chan KA. Incidence of health insurance claims for thyroid neoplasm and pancreatic malignancy in association with exenatide: signal refinement using active safety surveillance. Ther Adv Drug Saf. 2012 Aug;3(4):157-64. doi: 10.1177/2042098612446473. PMID: 25083233; PMCID: PMC4110848.
Copy Download .nbib Format: NLM
Novel Treatments in Neuroprotection for Aneurysmal Subarachnoid Hemorrhage.

Current treatment options in neurology

James RF, Kramer DR, Aljuboori ZS, Parikh G, Adams SW, Eaton JC, Abou Al-Shaar H, Badjatia N, Mack WJ, Simard JM.
PMID: 27325362
Curr Treat Options Neurol. 2016 Aug;18(8):38. doi: 10.1007/s11940-016-0421-6.

OPINION STATEMENT: New neuroprotective treatments aimed at preventing or minimizing "delayed brain injury" are attractive areas of investigation and hold the potential to have substantial beneficial effects on aneurysmal subarachnoid hemorrhage (aSAH) survivors. The underlying mechanisms for this "delayed...

Cite
James RF, Kramer DR, Aljuboori ZS, et al. Novel Treatments in Neuroprotection for Aneurysmal Subarachnoid Hemorrhage. Curr Treat Options Neurol. 2016;18(8):38doi: 10.1007/s11940-016-0421-6.
James, R. F., Kramer, D. R., Aljuboori, Z. S., Parikh, G., Adams, S. W., Eaton, J. C., Abou Al-Shaar, H., Badjatia, N., Mack, W. J., & Simard, J. M. (2016). Novel Treatments in Neuroprotection for Aneurysmal Subarachnoid Hemorrhage. Current treatment options in neurology, 18(8), 38. https://doi.org/10.1007/s11940-016-0421-6
James, Robert F, et al. "Novel Treatments in Neuroprotection for Aneurysmal Subarachnoid Hemorrhage." Current treatment options in neurology vol. 18,8 (2016): 38. doi: https://doi.org/10.1007/s11940-016-0421-6
James RF, Kramer DR, Aljuboori ZS, Parikh G, Adams SW, Eaton JC, Abou Al-Shaar H, Badjatia N, Mack WJ, Simard JM. Novel Treatments in Neuroprotection for Aneurysmal Subarachnoid Hemorrhage. Curr Treat Options Neurol. 2016 Aug;18(8):38. doi: 10.1007/s11940-016-0421-6. PMID: 27325362.
Copy Download .nbib Format: NLM
Impact of oral hypoglycemic agents on mortality among diabetic patients with non-muscle-invasive bladder cancer: A populationbased analysis.

Canadian Urological Association journal = Journal de l'Association des urologues du Canada

Richard PO, Ahmad AE, Bashir S, Zlotta A, Bhindi B, Leao R, Nayan M, Mohammed A, Fleshner NE, Kulkarni GS.
PMID: 29485035
Can Urol Assoc J. 2018 Jun;12(6):203-210. doi: 10.5489/cuaj.4870. Epub 2018 Feb 23.

INTRODUCTION: Non-muscle-invasive bladder cancer (NMIBC) accounts for 75-85% of all urothelial bladder cancers (UBC). Many UBC patients are also afflicted by diabetes mellitus (DM). It has been postulated that several oral hypoglycemic agents could impact disease-specific survival (DSS), but...

Cite
Richard PO, Ahmad AE, Bashir S, et al. Impact of oral hypoglycemic agents on mortality among diabetic patients with non-muscle-invasive bladder cancer: A populationbased analysis. Can Urol Assoc J. 2018;12(6):203-210doi: 10.5489/cuaj.4870.
Richard, P. O., Ahmad, A. E., Bashir, S., Zlotta, A., Bhindi, B., Leao, R., Nayan, M., Mohammed, A., Fleshner, N. E., & Kulkarni, G. S. (2018). Impact of oral hypoglycemic agents on mortality among diabetic patients with non-muscle-invasive bladder cancer: A populationbased analysis. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 12(6), 203-210. https://doi.org/10.5489/cuaj.4870
Richard, Patrick O, et al. "Impact of oral hypoglycemic agents on mortality among diabetic patients with non-muscle-invasive bladder cancer: A populationbased analysis." Canadian Urological Association journal = Journal de l'Association des urologues du Canada vol. 12,6 (2018): 203-210. doi: https://doi.org/10.5489/cuaj.4870
Richard PO, Ahmad AE, Bashir S, Zlotta A, Bhindi B, Leao R, Nayan M, Mohammed A, Fleshner NE, Kulkarni GS. Impact of oral hypoglycemic agents on mortality among diabetic patients with non-muscle-invasive bladder cancer: A populationbased analysis. Can Urol Assoc J. 2018 Jun;12(6):203-210. doi: 10.5489/cuaj.4870. Epub 2018 Feb 23. PMID: 29485035; PMCID: PMC5994977.
Copy Download .nbib Format: NLM
Effect of C-peptide Alone or in Combination with Nicotinamide on Glucose and Insulin Levels in Streptozotocin-Nicotinamide-Induced Type 2 Diabetic Mice.

The Malaysian journal of medical sciences : MJMS

Ahangarpour A, Ramezani Ali Akbari F, Fathi Moghadam H.
PMID: 25977616
Malays J Med Sci. 2014 Jul;21(4):12-7.

BACKGROUND: Both C-peptide and nicotinamide are known to reduce blood glucose in type 1 diabetes. In the present study, the effects of C-peptide alone or in combination with nicotinamide on glucose and insulin levels in streptozotocin-nicotinamide-induced type 2 diabetic...

Cite
Ahangarpour A, Ramezani Ali Akbari F, Fathi Moghadam H. Effect of C-peptide Alone or in Combination with Nicotinamide on Glucose and Insulin Levels in Streptozotocin-Nicotinamide-Induced Type 2 Diabetic Mice. Malays J Med Sci. 2014;21(4):12-7
Ahangarpour, A., Ramezani Ali Akbari, F., & Fathi Moghadam, H. (2014). Effect of C-peptide Alone or in Combination with Nicotinamide on Glucose and Insulin Levels in Streptozotocin-Nicotinamide-Induced Type 2 Diabetic Mice. The Malaysian journal of medical sciences : MJMS, 21(4), 12-7.
Ahangarpour, Akram, et al. "Effect of C-peptide Alone or in Combination with Nicotinamide on Glucose and Insulin Levels in Streptozotocin-Nicotinamide-Induced Type 2 Diabetic Mice." The Malaysian journal of medical sciences : MJMS vol. 21,4 (2014): 12-7.
Ahangarpour A, Ramezani Ali Akbari F, Fathi Moghadam H. Effect of C-peptide Alone or in Combination with Nicotinamide on Glucose and Insulin Levels in Streptozotocin-Nicotinamide-Induced Type 2 Diabetic Mice. Malays J Med Sci. 2014 Jul;21(4):12-7. PMID: 25977616; PMCID: PMC4418108.
Copy Download .nbib Format: NLM
Erratum to: The role of particle size of glyburide crystals in improving its oral absorption.

Drug delivery and translational research

Yang W, Wang Y, Fu Q, Guo Z, Sun B, Liu W, Liu Y, Mu S, Guo M, Li J, Pu X, He Z.
PMID: 28462500
Drug Deliv Transl Res. 2017 Oct;7(5):771. doi: 10.1007/s13346-017-0387-2.

No abstract available.

Cite
Yang W, Wang Y, Fu Q, et al. Erratum to: The role of particle size of glyburide crystals in improving its oral absorption. Drug Deliv Transl Res. 2017;7(5):771doi: 10.1007/s13346-017-0387-2.
Yang, W., Wang, Y., Fu, Q., Guo, Z., Sun, B., Liu, W., Liu, Y., Mu, S., Guo, M., Li, J., Pu, X., & He, Z. (2017). Erratum to: The role of particle size of glyburide crystals in improving its oral absorption. Drug delivery and translational research, 7(5), 771. https://doi.org/10.1007/s13346-017-0387-2
Yang, Wenqian, et al. "Erratum to: The role of particle size of glyburide crystals in improving its oral absorption." Drug delivery and translational research vol. 7,5 (2017): 771. doi: https://doi.org/10.1007/s13346-017-0387-2
Yang W, Wang Y, Fu Q, Guo Z, Sun B, Liu W, Liu Y, Mu S, Guo M, Li J, Pu X, He Z. Erratum to: The role of particle size of glyburide crystals in improving its oral absorption. Drug Deliv Transl Res. 2017 Oct;7(5):771. doi: 10.1007/s13346-017-0387-2. PMID: 28462500.
Copy Download .nbib Format: NLM
Oral Medications for Diabetes in Pregnancy: Use in a Rural Population.

Diabetes spectrum : a publication of the American Diabetes Association

Thorkelson SJ, Anderson KR.
PMID: 27182179
Diabetes Spectr. 2016 May;29(2):98-101. doi: 10.2337/diaspect.29.2.98.

IN BRIEF The oral agents glyburide and metformin are both recommended by many professional societies for the treatment of gestational diabetes mellitus (GDM). Both therapeutic modalities have published safety and efficacy data, but there remains much debate among experts....

Cite
Thorkelson SJ, Anderson KR. Oral Medications for Diabetes in Pregnancy: Use in a Rural Population. Diabetes Spectr. 2016;29(2):98-101doi: 10.2337/diaspect.29.2.98.
Thorkelson, S. J., & Anderson, K. R. (2016). Oral Medications for Diabetes in Pregnancy: Use in a Rural Population. Diabetes spectrum : a publication of the American Diabetes Association, 29(2), 98-101. https://doi.org/10.2337/diaspect.29.2.98
Thorkelson, Shelley Jayne, and Anderson, Kristi R. "Oral Medications for Diabetes in Pregnancy: Use in a Rural Population." Diabetes spectrum : a publication of the American Diabetes Association vol. 29,2 (2016): 98-101. doi: https://doi.org/10.2337/diaspect.29.2.98
Thorkelson SJ, Anderson KR. Oral Medications for Diabetes in Pregnancy: Use in a Rural Population. Diabetes Spectr. 2016 May;29(2):98-101. doi: 10.2337/diaspect.29.2.98. PMID: 27182179; PMCID: PMC4865390.
Copy Download .nbib Format: NLM
Management of gestational diabetes mellitus.

Diabetes, metabolic syndrome and obesity : targets and therapy

Lapolla A, Dalfrà MG, Fedele D.
PMID: 21437120
Diabetes Metab Syndr Obes. 2009 Jun 17;2:73-82. doi: 10.2147/dmsott.s3407.

The incidence of gestational diabetes mellitus (GDM) is on the increase and, if not diagnosed, managed and treated adequately, can have unfavorable maternal and fetal outcomes. Several studies have shown that glycemic values considered as adequate in the past...

Cite
Lapolla A, Dalfrà MG, Fedele D. Management of gestational diabetes mellitus. Diabetes Metab Syndr Obes. 2009;2:73-82doi: 10.2147/dmsott.s3407.
Lapolla, A., Dalfrà, M. G., & Fedele, D. (2009). Management of gestational diabetes mellitus. Diabetes, metabolic syndrome and obesity : targets and therapy, 273-82. https://doi.org/10.2147/dmsott.s3407
Lapolla, Annunziata, et al. "Management of gestational diabetes mellitus." Diabetes, metabolic syndrome and obesity : targets and therapy vol. 2 (2009): 73-82. doi: https://doi.org/10.2147/dmsott.s3407
Lapolla A, Dalfrà MG, Fedele D. Management of gestational diabetes mellitus. Diabetes Metab Syndr Obes. 2009 Jun 17;2:73-82. doi: 10.2147/dmsott.s3407. PMID: 21437120; PMCID: PMC3048015.
Copy Download .nbib Format: NLM
Oral Hypoglycemic Agents in pregnancy: An Update.

Journal of obstetrics and gynaecology of India

Kavitha N, De S, Kanagasabai S.
PMID: 24431611
J Obstet Gynaecol India. 2013 Apr;63(2):82-7. doi: 10.1007/s13224-012-0312-z. Epub 2013 Mar 27.

INTRODUCTION: Traditionally, insulin has been the gold standard in the management of Type 2 diabetes in pregnancy and gestational diabetes. However, insulin therapy can be inconvenient because of the needs for multiple injections, its associated cost, pain at the...

Cite
Kavitha N, De S, Kanagasabai S. Oral Hypoglycemic Agents in pregnancy: An Update. J Obstet Gynaecol India. 2013;63(2):82-7doi: 10.1007/s13224-012-0312-z.
Kavitha, N., De, S., & Kanagasabai, S. (2013). Oral Hypoglycemic Agents in pregnancy: An Update. Journal of obstetrics and gynaecology of India, 63(2), 82-7. https://doi.org/10.1007/s13224-012-0312-z
Kavitha, Nagandla, et al. "Oral Hypoglycemic Agents in pregnancy: An Update." Journal of obstetrics and gynaecology of India vol. 63,2 (2013): 82-7. doi: https://doi.org/10.1007/s13224-012-0312-z
Kavitha N, De S, Kanagasabai S. Oral Hypoglycemic Agents in pregnancy: An Update. J Obstet Gynaecol India. 2013 Apr;63(2):82-7. doi: 10.1007/s13224-012-0312-z. Epub 2013 Mar 27. PMID: 24431611; PMCID: PMC3664692.
Copy Download .nbib Format: NLM
New mechanisms for sulfonylurea control of insulin secretion.

Endocrine

Satin LS.
PMID: 21153274
Endocrine. 1996 Jun;4(3):191-8. doi: 10.1007/BF02738684.

Oral antidiabetic sulfonylureas like tolbutamide and glyburide have been used to treat patients with noninsulin dependent diabetes mellitus. These agents lower blood glucose by stimulating insulin secretion from the pancreatic islets of Langerhans. A major component of this stimulation...

Cite
Satin LS. New mechanisms for sulfonylurea control of insulin secretion. Endocrine. 1996;4(3):191-8doi: 10.1007/BF02738684.
Satin, L. S. (1996). New mechanisms for sulfonylurea control of insulin secretion. Endocrine, 4(3), 191-8. https://doi.org/10.1007/BF02738684
Satin, L S. "New mechanisms for sulfonylurea control of insulin secretion." Endocrine vol. 4,3 (1996): 191-8. doi: https://doi.org/10.1007/BF02738684
Satin LS. New mechanisms for sulfonylurea control of insulin secretion. Endocrine. 1996 Jun;4(3):191-8. doi: 10.1007/BF02738684. PMID: 21153274.
Copy Download .nbib Format: NLM
Gestational diabetes: screening for all, which test and which treatment?.

Expert review of endocrinology & metabolism

Visser GH, de Valk HW.
PMID: 30764007
Expert Rev Endocrinol Metab. 2012 Mar;7(2):165-167. doi: 10.1586/eem.12.7.

Gestational diabetes mellitus is rapidly increasing in incidence, due to lifestyle changes, increasing obesity and maternal age. This increase makes universal screening mandatory; however, we are still far from it. Moreover, should we adopt rather strict oral glucose tolerance...

Cite
Visser GH, de Valk HW. Gestational diabetes: screening for all, which test and which treatment?. Expert Rev Endocrinol Metab. 2012;7(2):165-167doi: 10.1586/eem.12.7.
Visser, G. H., & de Valk, H. W. (2012). Gestational diabetes: screening for all, which test and which treatment?. Expert review of endocrinology & metabolism, 7(2), 165-167. https://doi.org/10.1586/eem.12.7
Visser, Gerard Ha, and de Valk, Harold W. "Gestational diabetes: screening for all, which test and which treatment?." Expert review of endocrinology & metabolism vol. 7,2 (2012): 165-167. doi: https://doi.org/10.1586/eem.12.7
Visser GH, de Valk HW. Gestational diabetes: screening for all, which test and which treatment?. Expert Rev Endocrinol Metab. 2012 Mar;7(2):165-167. doi: 10.1586/eem.12.7. PMID: 30764007.
Copy Download .nbib Format: NLM
Sulfonylurea Class of Antidiabetic Drugs Inhibit Acetylcholinesterase Activity: Unexplored Auxiliary Pharmacological Benefit toward Alzheimer's Disease.

ACS pharmacology & translational science

Baruah P, Das A, Paul D, Chakrabarty S, Aguan K, Mitra S.
PMID: 33615172
ACS Pharmacol Transl Sci. 2021 Jan 06;4(1):193-205. doi: 10.1021/acsptsci.0c00168. eCollection 2021 Feb 12.

Contemporary literature documents extensive research on common causative mechanisms, pathogenic pathways and dual effective remedies for Alzheimer's disease (AD) and Type 2 diabetes mellitus (T2DM). Tolbutamide (TBM), chlorpropamide (CPM), and glyburide (GLY) are three sulfonylurea antidiabetic drugs of different...

Cite
Baruah P, Das A, Paul D, et al. Sulfonylurea Class of Antidiabetic Drugs Inhibit Acetylcholinesterase Activity: Unexplored Auxiliary Pharmacological Benefit toward Alzheimer's Disease. ACS Pharmacol Transl Sci. 2021;4(1):193-205doi: 10.1021/acsptsci.0c00168.
Baruah, P., Das, A., Paul, D., Chakrabarty, S., Aguan, K., & Mitra, S. (2021). Sulfonylurea Class of Antidiabetic Drugs Inhibit Acetylcholinesterase Activity: Unexplored Auxiliary Pharmacological Benefit toward Alzheimer's Disease. ACS pharmacology & translational science, 4(1), 193-205. https://doi.org/10.1021/acsptsci.0c00168
Baruah, Prayasee, et al. "Sulfonylurea Class of Antidiabetic Drugs Inhibit Acetylcholinesterase Activity: Unexplored Auxiliary Pharmacological Benefit toward Alzheimer's Disease." ACS pharmacology & translational science vol. 4,1 (2021): 193-205. doi: https://doi.org/10.1021/acsptsci.0c00168
Baruah P, Das A, Paul D, Chakrabarty S, Aguan K, Mitra S. Sulfonylurea Class of Antidiabetic Drugs Inhibit Acetylcholinesterase Activity: Unexplored Auxiliary Pharmacological Benefit toward Alzheimer's Disease. ACS Pharmacol Transl Sci. 2021 Jan 06;4(1):193-205. doi: 10.1021/acsptsci.0c00168. eCollection 2021 Feb 12. PMID: 33615172; PMCID: PMC7887854.
Copy Download .nbib Format: NLM
Changing patterns in medication prescription for gestational diabetes during a time of guideline change in the USA: a cross-sectional study.

BJOG : an international journal of obstetrics and gynaecology

Venkatesh KK, Chiang CW, Castillo WC, Battarbee AN, Donneyong M, Harper LM, Costantine M, Saade G, Werner EF, Boggess KA, Landon MB.
PMID: 34605130
BJOG. 2022 Feb;129(3):473-483. doi: 10.1111/1471-0528.16960. Epub 2021 Nov 08.

OBJECTIVE: To define patterns of prescription and factors associated with choice of pharmacotherapy for gestational diabetes mellitus (GDM), namely metformin, glyburide and insulin, during a period of evolving professional guidelines.DESING: Cross-sectional study.SETTING: US commercial insurance beneficiaries from Market-Scan (late...

Cite
Venkatesh KK, Chiang CW, Castillo WC, et al. Changing patterns in medication prescription for gestational diabetes during a time of guideline change in the USA: a cross-sectional study. BJOG. 2021;129(3):473-483doi: 10.1111/1471-0528.16960.
Venkatesh, K. K., Chiang, C. W., Castillo, W. C., Battarbee, A. N., Donneyong, M., Harper, L. M., Costantine, M., Saade, G., Werner, E. F., Boggess, K. A., & Landon, M. B. (2022). Changing patterns in medication prescription for gestational diabetes during a time of guideline change in the USA: a cross-sectional study. BJOG : an international journal of obstetrics and gynaecology, 129(3), 473-483. https://doi.org/10.1111/1471-0528.16960
Venkatesh, K K, et al. "Changing patterns in medication prescription for gestational diabetes during a time of guideline change in the USA: a cross-sectional study." BJOG : an international journal of obstetrics and gynaecology vol. 129,3 (2022): 473-483. doi: https://doi.org/10.1111/1471-0528.16960
Venkatesh KK, Chiang CW, Castillo WC, Battarbee AN, Donneyong M, Harper LM, Costantine M, Saade G, Werner EF, Boggess KA, Landon MB. Changing patterns in medication prescription for gestational diabetes during a time of guideline change in the USA: a cross-sectional study. BJOG. 2022 Feb;129(3):473-483. doi: 10.1111/1471-0528.16960. Epub 2021 Nov 08. PMID: 34605130; PMCID: PMC8752504.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 122 entries